<html>
<body bgcolor="#030303" >
<table align="center" border="1" style="width: 90%; height: 80%;">
<tbody>
<tr>
<td height="420" valign="top" bgcolor="#CCCCCC" style="padding-top:
10px;">
<table align="center" border="1" style="width: 98%;">
<tbody>
<tr bgcolor="#4388a2">
<td height="77">
<p align="center " style="font-family:
'Tahoma',Helvetica; padding: 10px 0px 5px 0px; margin: 0px; color: #765e31; font-size:
24px; font-weight: bold; letter-spacing: -1px; display:
block; border-bottom: dashed 1px #ccc;"><span style="font-size:
x-large;">Nuvilex Inc. (NVLX)</span></p>
<p align="left" color:="" 765e31="" 8b661f="" 9b6a0d=""
b47908=""><strong><em><strong><em><b>Nuvilex, Inc. Now
Manages Usage of Live
Cell Encapsulation Technology for Any Type of Can_cer by Any
Entity</b></em></strong></em></strong></p>
</td>
</tr>
<tr bgcolor="#86b5c7">
<td height="202">
<p><br />When <b>Nuvilex, Inc.</b> (OTCQB: <b>NVLX</b>)
attained all of the shares of Bio Blue Bird
AG from SG Austria Pri-vate Limited what may have been confused in
all the legal lingo of last week’s
purc_hase is that Nuvilex now
controls the use of this technology as it
correlates to its use in any
treatment, of any form of can_cer, by any
entity. This update by itself could not
only significantly
enrich Nuvilex’s pipeline, but could
draw many of
big name pharmaceutical and biotech companies to
Nuvilex’s threshold. The key, obviously, is
Nuvilex’s future Level
Three pancreas can_cer trials.</p>
<p>This is a agreement where Nuvilex and
their shareholders win huge, and quite
candidly the
shift was pure brilliance and may
show to be valued bil_lions of
dol_lars. Can_cer is big, big business and Nuvilex
carried out that which can only be
called as the barg_ain
of the century. The entity was
able to secure a deal that
all_owed them to “cherry-pick” the
precise piece of the pie Nuvilex
required from a different
entity. And, what was the
precise piece of the pie Nuvilex sought out
– Bio Blue Bird AG and, more
notably, its
global licenses associated with the live-cell encapsulation platform technology to
foster therapies for all can_cer types
– and that’s precisely what the
organization got.<br /> <br />75 Arlington
ST, STE 500, Boston, Massachusetts
02116 USA <br /> </p>
</td>
</tr>
</tbody>
</table>
<table align="center" border="1" style="width: 98%;">
<tbody>
<tr>
<td bgcolor="#b3d3df">
<p align="left" style="font-family: 'Verdana'; font-size: 9px;
color: #fff; text-align: center;"><span
style="font-family: Tahoma, helvetica, sans-serif;
font-size: x-small;">The use of research materials circulated by the
auth.or is done at your own risk. You are encouraged to do your own
research before making any investment decision in regards to the secu rity
discussed herein. The author has not been rewarded by any entity in
connection with the distribution of these materials. You should presume
that as of the date of this report or letter, the author, possibly along
with or through our owners, affiliates, employees and/or consultants,
(cooperatively referred to as the author) has a position in all company
shares (and/or options of the shares) covered herein that is consistent
with the position set forth in our report. In connection with NVLX, the
author has taken a long position. Following the disbursement of any report
or letter, the author intends to continue engaging in trnsactns in the secu
rity covered herein, and we may be long, short, and/or neutral at any time
hereafter regardless of our initial position and we preserve the right to
procure or trade all or part of our position at any time without notice.
This practice could end in our trading securities at any time before,
during, and/or after the disbursement of this report.<br /> <br
/><strong><a
href="http://support.futzona.net/unsubscribe.php?M=6588707&C=0a89a74737fe0ab850bde605efc11be4&L=54&N=1312">Unsubscribe</a></strong></span></p>
</td>
</tr>
</tbody>
</table>
</td>
</tr>
<tr></tr>
</tbody>
</table>
<img
src="http://support.futzona.net/open.php?M=6588707&L=54&N=1312&F=H&image=.jpg"
height="1" width="10"></body>